MX2009012891A - Proteinas de union a antigeno dirigidas a staphylococcus aureus orf0657n. - Google Patents
Proteinas de union a antigeno dirigidas a staphylococcus aureus orf0657n.Info
- Publication number
- MX2009012891A MX2009012891A MX2009012891A MX2009012891A MX2009012891A MX 2009012891 A MX2009012891 A MX 2009012891A MX 2009012891 A MX2009012891 A MX 2009012891A MX 2009012891 A MX2009012891 A MX 2009012891A MX 2009012891 A MX2009012891 A MX 2009012891A
- Authority
- MX
- Mexico
- Prior art keywords
- binding proteins
- antigen
- aureus
- orf0657n
- proteins targeting
- Prior art date
Links
- 102000025171 antigen binding proteins Human genes 0.000 title abstract 2
- 108091000831 antigen binding proteins Proteins 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a proteínas de unión a antígeno que se unen a una región que se ha encontrado que tiene un epítope que puede ser dirigido para proveer protección contra infección por S. aureus; la región se designa aquí como la región objetivo "CS-D7"; la región objetivo CS-D7 provee un epítope de S. aureus ORF0657n que puede ser dirigido para reducir la probabilidad o severidad de una infección por S. aureus.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93278807P | 2007-05-31 | 2007-05-31 | |
US799807P | 2007-12-17 | 2007-12-17 | |
PCT/US2008/006791 WO2009029132A2 (en) | 2007-05-31 | 2008-05-29 | Antigen-binding proteins targeting s. aureus orf0657n |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009012891A true MX2009012891A (es) | 2009-12-10 |
Family
ID=40380548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009012891A MX2009012891A (es) | 2007-05-31 | 2008-05-29 | Proteinas de union a antigeno dirigidas a staphylococcus aureus orf0657n. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20100166772A1 (es) |
EP (1) | EP2164869A2 (es) |
JP (1) | JP2010528607A (es) |
KR (1) | KR20100021577A (es) |
CN (1) | CN101679516B (es) |
AU (1) | AU2008294038A1 (es) |
BR (1) | BRPI0811193A2 (es) |
CA (1) | CA2687681A1 (es) |
IL (1) | IL201906A0 (es) |
MX (1) | MX2009012891A (es) |
RU (1) | RU2009149294A (es) |
WO (1) | WO2009029132A2 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101375161A (zh) * | 2006-01-27 | 2009-02-25 | 默克公司 | 靶定金黄色葡萄球菌ORF0657n的抗原结合蛋白 |
US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
JP5658564B2 (ja) | 2007-08-31 | 2015-01-28 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物 |
US8758765B2 (en) | 2008-07-29 | 2014-06-24 | The University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
BRPI1010307B1 (pt) | 2009-04-03 | 2021-07-27 | University Of Chicago | Polipeptídeos variantes de proteína a (spa), composição imunogênica compreendendo os mesmos, vacina, método de produção da referida vacina, bem como uso dos referidos polipeptídeos |
NZ612315A (en) | 2009-04-14 | 2014-10-31 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
CA2779798C (en) | 2009-09-30 | 2019-03-19 | Novartis Ag | Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides |
US20120208986A1 (en) * | 2009-10-20 | 2012-08-16 | Wenger Marc D | Use of mixed mode chromatography for the capture and purification of basic antibody products |
CN102971009A (zh) | 2009-10-30 | 2013-03-13 | 诺华有限公司 | 金黄色葡萄球菌5型和8型荚膜多糖的纯化 |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
ES2655701T3 (es) | 2010-07-02 | 2018-02-21 | The University Of Chicago | Composiciones y métodos relacionados con variantes de la proteína A (SpA) |
CA2826566C (en) * | 2011-02-08 | 2022-09-13 | Medimmune, Llc | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
CN102649817A (zh) * | 2011-02-24 | 2012-08-29 | 复旦大学 | 一种抑制细菌生物膜形成的单克隆抗体 |
US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
WO2013096948A1 (en) | 2011-12-23 | 2013-06-27 | Lydon Nicholas B | Immunoglobulins and variants directed against pathogenic microbes |
KR102100009B1 (ko) | 2016-05-04 | 2020-04-10 | 이길봉 | 3축 트레일러의 조향장치 |
KR20170003596U (ko) | 2017-06-16 | 2017-10-17 | 배경률 | 자동차용 스노우 체인 |
CA3076632A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6916605B1 (en) * | 1990-07-10 | 2005-07-12 | Medical Research Council | Methods for producing members of specific binding pairs |
US6610293B1 (en) | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
US7250494B2 (en) | 1998-06-15 | 2007-07-31 | Biosynexus Incorporated | Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria |
PT2281843T (pt) * | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
US7138496B2 (en) * | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
EP1377314B1 (en) * | 2001-01-26 | 2011-09-14 | Inhibitex, Inc. | Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections |
CN1615315A (zh) * | 2001-11-19 | 2005-05-11 | 应用分子发展公司 | 肿瘤特异性单克隆抗体 |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
NZ570750A (en) * | 2003-07-24 | 2009-12-24 | Merck & Co Inc | Polypeptides for inducing a protective immune response against staphylococcus aureus |
US20070134263A1 (en) | 2004-02-18 | 2007-06-14 | Anderson Annaliesa S | Polypeptides for inducing a protective immune response against staphyloococcus aureus |
WO2005086663A2 (en) | 2004-02-27 | 2005-09-22 | Merck & Co., Inc. | Polypeptides for inducing a protective immune response against staphlococcus aureus |
US20070243205A1 (en) | 2004-05-25 | 2007-10-18 | Anderson Annaliesa S | Polypeptides for Inducing a Protective Immune Response Against Staphylococcus Aureus |
WO2006033918A2 (en) | 2004-09-17 | 2006-03-30 | Merck & Co., Inc. | Polypeptides for inducing a protective immune response against staphylococcus aureus |
AU2006206577B2 (en) | 2005-01-21 | 2012-03-08 | Merck Sharp & Dohme Corp. | Polypeptides for inducing a protective immune response against Staphylococcus aureus |
CN1320125C (zh) * | 2005-09-28 | 2007-06-06 | 兰州生物制品研究所 | 一种单克隆抗体的制备方法及其应用 |
CN101375161A (zh) * | 2006-01-27 | 2009-02-25 | 默克公司 | 靶定金黄色葡萄球菌ORF0657n的抗原结合蛋白 |
EP2027155B1 (en) * | 2006-06-06 | 2016-01-27 | Crucell Holland B.V. | Human binding molecules having killing activity against staphylococci and uses thereof |
WO2007141278A2 (en) * | 2006-06-06 | 2007-12-13 | Crucell Holland B.V. | Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof |
-
2008
- 2008-05-29 RU RU2009149294/10A patent/RU2009149294A/ru not_active Application Discontinuation
- 2008-05-29 CA CA002687681A patent/CA2687681A1/en not_active Abandoned
- 2008-05-29 BR BRPI0811193-6A2A patent/BRPI0811193A2/pt not_active IP Right Cessation
- 2008-05-29 CN CN2008800176016A patent/CN101679516B/zh not_active Expired - Fee Related
- 2008-05-29 KR KR1020097024900A patent/KR20100021577A/ko not_active Application Discontinuation
- 2008-05-29 EP EP08828478A patent/EP2164869A2/en not_active Withdrawn
- 2008-05-29 MX MX2009012891A patent/MX2009012891A/es active IP Right Grant
- 2008-05-29 US US12/601,933 patent/US20100166772A1/en not_active Abandoned
- 2008-05-29 JP JP2010510333A patent/JP2010528607A/ja active Pending
- 2008-05-29 WO PCT/US2008/006791 patent/WO2009029132A2/en active Application Filing
- 2008-05-29 AU AU2008294038A patent/AU2008294038A1/en not_active Abandoned
-
2009
- 2009-11-03 IL IL201906A patent/IL201906A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2164869A2 (en) | 2010-03-24 |
IL201906A0 (en) | 2010-06-16 |
RU2009149294A (ru) | 2011-07-10 |
CN101679516A (zh) | 2010-03-24 |
WO2009029132A2 (en) | 2009-03-05 |
JP2010528607A (ja) | 2010-08-26 |
KR20100021577A (ko) | 2010-02-25 |
CN101679516B (zh) | 2013-11-13 |
BRPI0811193A2 (pt) | 2014-11-11 |
US20100166772A1 (en) | 2010-07-01 |
AU2008294038A1 (en) | 2009-03-05 |
CA2687681A1 (en) | 2009-03-05 |
WO2009029132A3 (en) | 2009-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009012891A (es) | Proteinas de union a antigeno dirigidas a staphylococcus aureus orf0657n. | |
MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
UA111818C2 (uk) | Антитіло проти csf-1r | |
UA117901C2 (uk) | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування | |
PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
MY166776A (en) | Humanised anti-ctla4 antibodies | |
EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
JO3118B1 (ar) | تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة | |
WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
BR112013020086A2 (pt) | anticorpos que se ligam especificamente à alfa-toxina de staphylococcus aureus e métodos de utilização | |
WO2011119979A3 (en) | Antibodies to muc16 and methods of use thereof | |
EA201000903A1 (ru) | Антитела к pcrv-антигену pseudomonas aeruginosa | |
WO2009112245A9 (en) | Antibody against the csf-1 r | |
BR112014002758A2 (pt) | composições para cuidados pessoais contendo zinco piritiona submetido à secagem | |
WO2008097439A3 (en) | Anti-autoimmune antibodies for treatment of pemphigus | |
WO2011004028A3 (en) | Tlr3 binding agents | |
JO3437B1 (ar) | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها | |
NZ607615A (en) | Antibodies directed against il-17 | |
WO2009114560A3 (en) | Compositions and methods for the therapy and diagnosis of cytomegalovirus infections | |
BRPI1010911A2 (pt) | "anticorpos ou fragmentos destes direcionados contra um epitopo de staphylococcus aureus" | |
EA201070826A1 (ru) | Антитела против pcrv | |
MX2011009100A (es) | Anticuerpo humanizado pcrv que tiene actividad anti-pseudomonal. | |
NZ702282A (en) | Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease | |
WO2012031260A3 (en) | Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof | |
WO2011123819A3 (en) | Epha3 antibodies for the treatment of multiple myeloma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
HC | Change of company name or juridical status | ||
FG | Grant or registration | ||
GB | Transfer or rights | ||
HC | Change of company name or juridical status |